Anti-IDH1 R132H (clone QM002)

Monoclonal Antibody Specific for IDH1 R132H Point Mutation – A Key Diagnostic Marker in Brain Tumors
The monoclonal antibody specific for the IDH1 R132H point mutation is characterized by:
✔ Strong immunohistochemical staining (IHC)
✔ Consistent performance and reliability
✔ Absence of non-specific background staining
These features make it highly useful for detecting mutant IDH1 in FFPE tissue sections, facilitating the diagnosis and classification of brain tumors according to the WHO classification.
IDH1 – Wild-Type and Mutant Form
Isocitrate dehydrogenase 1 (IDH1) is an enzyme that catalyzes the third step of the citric acid cycle, converting isocitrate into alpha-ketoglutarate and releasing CO₂.
✔ Localization: Cytoplasm and peroxisomes
✔ Presence: Widely expressed across species, including organisms that lack a complete Krebs cycle
Mutations in IDH1 most commonly involve a missense substitution at codon 132, leading to:
✔ Loss of normal enzymatic function
✔ Abnormal production of 2-hydroxyglutarate (2HG)
✔ Inhibition of alpha-ketoglutarate-dependent enzymes (including histone and DNA demethylases)
✔ Widespread histone and DNA methylation changes, which may contribute to tumorigenesis
IDH1 R132H – A Key Mutation in Neuropathology
The IDH1 R132H point mutation is found in over 70% of gliomas, particularly in:
✔ WHO Grade II and III gliomas
✔ Secondary glioblastoma (WHO Grade IV)
The high prevalence of IDH1 mutations in oligodendroglial tumors makes it a critical marker in distinguishing oligodendrogliomas from other clear-cell neoplasms.
IDH1 status can be assessed via IHC to detect the mutant protein; however, if negative or inconclusive, further DNA-based analysis is required.
Clinical Significance of IDH1 Mutation
✔ IDH1 mutation has both diagnostic and prognostic value in primary brain tumors.
✔ Tumors with IDH1 mutations are associated with better overall prognosis.
IDH1 R132H Mutation in Other Cancers
Research has identified IDH1 mutations in various malignancies, including:
✔ Acute myeloid leukemia (AML)
✔ Acute lymphoblastic leukemia (ALL)
✔ Cholangiocarcinoma
✔ Chondrosarcomas
✔ Prostate cancer
✔ Papillary breast carcinoma
✔ Melanoma
✔ Angioimmunoblastic T-cell lymphoma
✔ Primary myelofibrosis
The presence of IDH1 mutations suggests a broader oncogenic role for this enzyme, making it an important diagnostic and therapeutic target across different cancer types.